Bevacizumab (Avastin-class) dose

Hospital buy vs billed (illustrative WAC/GPO/340B blend) Specialty / biosimilar / 340B

What the hospital pays (acquisition)$3,600

Cash$5,900

Medicaid$3,300

Medicare$3,900

Insured$8,100

Medicaid

$3,300

Medicare

$3,900

Cash

$5,900

Insured

$8,100

Insured path is $2,200 (37%) above cash. Hospital buy $3,600 vs insured $8,100.

Payers: modeled — see evidence.